October 2014 in “Cancer research” This study found that targeting mTORC1 with rapamycin effectively inhibited skin tumor promotion in a mouse model, highlighting a potential target for cancer chemoprevention.
6 citations
,
February 2022 in “The journal of neuroscience/The Journal of neuroscience” This study observed that deleting PTEN in mouse facial motoneurons enhanced peripheral axon regeneration but also led to physiological changes and potential hyperplasia in older mice.
September 2023 in “Frontiers in medicine” This review suggests that the mTOR signaling pathway may play a significant role in hair follicle health by influencing the effects of Vitamin D receptor deficiency, potentially contributing to hair follicle damage and related hair loss conditions.
82 citations
,
September 2018 in “Nature Communications” This study found that stimulating the olfactory receptor OR2AT4 in human hair follicles with a synthetic sandalwood odorant promotes hair growth ex vivo by decreasing apoptosis and increasing IGF-1 production.
6 citations
,
March 2021 in “Journal of Cosmetic Dermatology” In this study, platelet-rich plasma treatment improved hair regrowth and characteristics in mice and showed therapeutic efficacy in Chinese patients with androgenetic alopecia.
1 citations
,
December 2025 in “Frontiers in Endocrinology” This review examines the potential role of gut microbiota and its metabolites in polycystic ovary syndrome (PCOS) and highlights the growing interest in this area; it reports no new clinical findings.
April 2025 in “Cellular and Molecular Biology” This study found that human dermal stem/progenitor cells demonstrated greater proliferation and differentiation potential than hair follicle dermal papilla cells, which showed increased expression of hair regeneration markers.
January 2023 in “Åbo Akademi University Research Portal” This study found that vimentin is essential for proper wound healing and cell growth by influencing EMT signaling and mTOR activity in mice.
2 citations
,
May 2015 in “PloS one” This study found that radiation negatively impacts the survival and proliferation of fibroblasts on human dermis transplants, but hair follicle pores enhance cell viability even after irradiation.
65 citations
,
February 2011 in “Molecular cancer therapeutics” This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.
8 citations
,
September 2013 in “Molecular carcinogenesis” This study found that rapamycin effectively inhibits TPA-induced keratinocyte proliferation and skin tumor promotion by targeting mTORC1 signaling in both wild-type and transgenic mice.
April 2012 in “Cancer research” In this study, the authors found that targeting mTORC1 with rapamycin inhibited TPA-induced skin tumor promotion by affecting keratinocyte proliferation, including critical stem cell populations in the mouse epidermis.
February 2006 in “Inpharma Weekly” February 2026 in “European Urology”
The document cannot be summarized as it is not provided or is unclear.
13 citations
,
September 2011 in “International Urology and Nephrology” October 2012 in “Sax's Dangerous Properties of Industrial Materials”
June 2019 in “Reactions Weekly” 505 citations
,
October 2011 in “Journal of clinical oncology” This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.
180 citations
,
February 2023 in “Journal of Chemical Information and Modeling” In this paper, Chemistry42—a software integrating AI with computational and medicinal chemistry—demonstrated efficiency in designing novel molecular structures targeting DDR1 and CDK20, with properties validated in both in vitro and in vivo studies.
177 citations
,
March 2018 in “International Journal of Molecular Sciences” This review discusses the role of mTOR kinase in pulmonary fibrosis and explores how mTOR inhibitors may help slow the progression of this condition, but it reports no new results.
110 citations
,
February 2024 in “Journal of Chemical Information and Modeling” This study describes the PandaOmics platform, which uses AI and bioinformatics to identify new therapeutic targets and biomarkers for various diseases, demonstrating validation in laboratory and animal studies.
35 citations
,
July 2022 in “Frontiers in Cell and Developmental Biology” This review discusses the role of mTOR signaling in the epidermis, emphasizing its importance in skin processes like barrier formation and wound repair, and reports no new experimental results.
9 citations
,
June 2023 in “Cells” This review summarizes recent findings on how the dysregulated PI3K/Akt/mTOR pathway contributes to immune-mediated inflammatory skin disorders and discusses the potential of natural products, synthetic compounds, and biologic agents in their treatment. However, it emphasizes the need for further research to develop effective therapies.
April 2026 in “International Journal of Molecular Sciences” This study reviews evidence that in keloid development, transforming growth factor-β (TGF-β) drives fibroblast proliferation and fibrosis not only through the classical Smad-dependent pathway but also via equally important Smad-independent signaling cascades, suggesting these pathways as possible targets for more effective keloid therapies.
June 2018 in “International Review of Intellectual Property and Competition Law”
16 citations
,
May 2000 in “Endocrinology” This study identified a new gene, mrp4, in mice, which suggests it may have a unique role in the growth and development of hair follicles in the ears and tails.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This document promotes a 25% discount using the code ARPT on Soulflower's natural and organic beauty products, with no new research findings reported.
September 2010 in “European Urology Supplements”
3 citations
,
January 2019 in “Therapeutic advances in urology” This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.